"T"-ing off on nasopharynx cancer.
Nasopharyngeal carcinoma (NPC) is the most frequent Epstein-Barr virus (EBV)-associated malignancy worldwide. In this issue, Straathof and colleagues take aim at EBV-associated NPC showing that adoptive immunotherapy with EBV-specific T cells expanded in vitro can be successfully administered to NPC patients and is associated with potential therapeutic efficacy.
Wang
Fred
F
Harvard Medical School, Boston, MA, USA.
D018929:Cell Culture Techniques; D004854:Herpesvirus 4, Human / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods; D009303:Nasopharyngeal Neoplasms / Q000628:therapy* / Q000821:virology; D037182:T-Cell Antigen Receptor Specificity; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation; D016896:Treatment Outcome